Alireza Eghtedar
University of Texas MD Anderson Cancer Center
8 Papers
1 Citations
Alireza Eghtedar is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide
Alireza Eghtedar,Ildefonso Rodriguez,Hagop M. Kantarjian,Susan O'Brien,Naval Daver,Guillermo Garcia-Manero,Alessandra Ferrajoli,Tapan M. Kadia,Sherry Pierce,Jorge E. Cortes,Farhad Ravandi +10 more
TL;DR: Treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers adjusted for unit time of exposure.
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia
Alireza Eghtedar,Gautam Borthakur,Farhad Ravandi,Elias Jabbour,Jorge E. Cortes,Sherry Pierce,Hagop M. Kantarjian,Guillermo Garcia-Manero +7 more
TL;DR: The natural history of patients with t(16:16)(p13;q22) is similar to that of classic patients with inv16 AML and therefore should be treated similarly.
15
A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma
Mark B. Juckett,Sham Mailankody,Alireza Eghtedar,Cara Bickers,Xingyue Zong,Lilly Wong,Thomas Ly,John Byon,Sarah Cooley,Bahram Valamehr,Yu-Waye Chu,Ravi Vij +11 more
TL;DR: In this paper , an off-the-shelf, multiplexed-engineered allogeneic natural killer (NK) cell therapy was used to treat relapsed/refractory (R/R) multiple myeloma (MM) patients.
5
Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
Suman Kambhampati,Christine McMahon,Alireza Eghtedar,Daniel A. Pollyea,Stéphane de Botton,Arnaud Pigneux,Mohamad Cherry,Brian Ball,Gautam Borthakur,Thomas Cluzeau,Gary J. Schiller,Beibei Hu,Angela Volkert,Joanie Aasen Gausman,Graeme Hodgson,David A. Roth,Erica D. Warlick,Michael J. Kelly,Eytan M. Stein +18 more
TL;DR: The tamibarotene/azacitidine combination was well-tolerant with no increase in myelosuppression compared to azacetidine (aza) alone as mentioned in this paper .
2
AML-108 SELECT-AML-1 Trial in Progress: A Phase 2 Study of Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-Positive AML who are Ineligible for Standard Induction Therapy.
Suman Kambhampati,Alireza Eghtedar,Christine McMahon,Stéphane de Botton,Arnaud Pigneux,Brian Ball,Gautam Borthakur,Angela Volkert,Joanie Aasen Gausman,K. Baker,Graeme Hodgson,Erica D. Warlick,David A. Roth,Michael Kelly,Daniel A. Pollyea,Eytan M. Stein +15 more
TL;DR: A phase 2, open-label, multi-center trial comparing the activity of tamibarotene/venetoclax/azacitidine with that of venetocyte-derived RARA+ unfit AML patients was presented in this paper .